Medications may be used in conjunction with non-pharmacological treatments to manage cognition, function and behaviour in people with Alzheimer’s disease.

This article aims to provide evidence-based information to GPs, aiding the decision to initiate sodium–glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease patients.

Evidence supports a patient-centred approach to proton pump inhibitor deprescribing involving stepping down the dose before ceasing or switching to pro re nata use.

A case of euglycaemic diabetic ketoacidosis in a patient with latent autoimmune diabetes in adults using dapagliflozin.

Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.